Daré Bioscience
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
3655 Nobel Dr Ste 260, San Diego, Califo...Phone Number
(858) 926-7655Website
www.darebioscience.comRevenue
<$5 MillionStock Symbol
DAREIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Daré Bioscience
Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for womens health. The companys mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women, primarily in the areas of contraception, vaginal health, sexual health, and fertility.Explore more
Daré Bioscience Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Daré Bioscience your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Daré Bioscience recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Daré Bioscience has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Daré Bioscience
Check out if Daré Bioscience is spiking on competitors!
Click to see if Daré Bioscience had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Daré Bioscience has new funding data
Daré Bioscience, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Daré Bioscience launches new products
Recommended Actions
Find VP level buyers at Daré Bioscience
Find 3 more new buyers
Compare Similar Companies to Daré Bioscience
Compare insights from companies similar to Daré Bioscience, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Daré Bioscience is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Daré Bioscience is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Daré Bioscience.
Daré Bioscience financials insights
Gather financial insights about Daré Bioscience, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Multiple Rounds
$22.1M
2023
Other Financing Round
$12M
2024
Grant
$2.5M
Daré Bioscience Tech Stack
A closer look at the technologies used by Daré Bioscience
Most Recent Scoops
Project
Daré Bioscience is currently conducting a Phase 3 registration trial for Ovaprene, a once-a-month, non-hormonal vaginal contraceptive that physically blocks sperm and releases a spermiostatic agent to interfere with sperm motility, with interim data indicating 86 to 91% typical use effectiveness and two positive Data Safety Monitoring Board reviews requiring no study changes. The product has the potential to become the first FDA-approved monthly hormone-free contraceptive, with clinical data readout expected next year.
Product Development, Medical Research, Pharmaceuticals, Clinical Operations
Project
Daré Bioscience has initiated a Phase 2 clinical trial for DARE-HPV, an investigational at-home antiviral treatment for high-risk HPV infection, fully funded by a grant and contract with ARPA-H, based on a completed pilot study demonstrating proof of concept. The product has the potential to become the first FDA-approved pharmacologic treatment for high-risk HPV infection, with data expected next year.
Proof of Concept (POC), Clinical Operations
Project
Daré Bioscience is preparing for a Phase 2 study of a non-hormonal investigational treatment for Genitourinary Syndrome of Menopause (GSM), targeting women who cannot take hormones including hormone receptor-positive breast cancer survivors following a completed Phase 1/2 study that demonstrated statistically significant improvements in GSM symptoms. The product has the potential to become the first intravaginal treatment approved for this condition.
Medical Research, Pharmaceuticals, Clinical Operations
Product Launch
Daré Bioscience has announced plans to launch a once-a-month vaginal ring hormone therapy product under the Dare to Reclaim family, designed to deliver combined estradiol and progesterone for menopausal women with a uterus an unmet need under current Menopause Society guidelines with clinical studies demonstrating statistically significant improvements in hot flashes, night sweats, vaginal symptoms, and quality of life measures. The product is being advanced as a 503(b) compounded product while the NDA pathway development continues, with commercial launch targeted for next year.
Product Launch, Medical Research, Pharmaceuticals, Clinical Operations
Person-Based
Events, Finance, Investor Relations
Daré Bioscience News & Media
Daré Bioscience Announces $6.0 Million Registered Direct Offering and Concurrent Private ...
Financial news and insights from Quiver QuantitativeDaré Bioscience Announces Pricing of $6.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
SAN DIEGO, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (Nasdaq: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today announced that it has entered into a definitive securities purchase agreement with institutional investors for the purchase and sale of 4,379,581 shares of the Company’s common stock (or pre-funded warrants to purchase shares of common stock in lieu thereof), at aDaré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women’s Health Strategy Advances
Company launches Flora Sync LF5™, the company's first directly commercialized product, began generating revenue in JulyDaré Bioscience, Inc. (DARE) Discusses Portfolio Advancements and Therapeutic Solutions for Women's Health Transcript
Daré Bioscience, Inc. (DARE) Discusses Portfolio Advancements and Therapeutic Solutions for Women's Health August 11, 2026 12:30 PM EDTCompany...
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Daré Bioscience
Sign Up For FreeTo access detailed company insights
Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for womens health. The companys mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women, primarily in the a... Read More
